These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 17065014)
1. Continuous infusion of amphotericin B deoxycholate: does decreased nephrotoxicity couple with time-dependent pharmacodynamics? de Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Ranieri VM; di Perri G Leuk Lymphoma; 2006 Sep; 47(9):1964-6. PubMed ID: 17065014 [No Abstract] [Full Text] [Related]
2. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule. Altmannsberger P; Holler E; Andreesen R; Krause SW J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868 [No Abstract] [Full Text] [Related]
3. Is 24 hours infusion of amphotericin B deoxycholate as good as liposomal amphotericin B? Flückiger U Swiss Med Wkly; 2002 Aug; 132(31-32):431-2. PubMed ID: 12457300 [No Abstract] [Full Text] [Related]
4. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis. Falagas ME; Karageorgopoulos DE; Tansarli GS PLoS One; 2013; 8(10):e77075. PubMed ID: 24204739 [TBL] [Abstract][Full Text] [Related]
5. Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies. Schulenburg A; Sperr W; Rabitsch W; Knöbl P; Thalhammer F Leuk Lymphoma; 2005 Aug; 46(8):1163-7. PubMed ID: 16085557 [TBL] [Abstract][Full Text] [Related]
6. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate. Maharom P; Thamlikitkul V J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252 [TBL] [Abstract][Full Text] [Related]
7. Minimizing nephrotoxicity using continuous infusion of deoxycholate amphotericin B. Gwee A; Cranswick N; Connell TG; Curtis N Pediatr Infect Dis J; 2014 Oct; 33(10):1098. PubMed ID: 25361191 [No Abstract] [Full Text] [Related]
8. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K; Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454 [TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC. Uehara RP; Sá VH; Koshimura ET; Prudente FV; Tucunduva LT; Gonçalves MS; Samano ES; del Giglio A Sao Paulo Med J; 2005 Sep; 123(5):219-22. PubMed ID: 16358096 [TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections? Schneemann M; Bachli EB Clin Infect Dis; 2004 Jan; 38(2):303-4; author reply 306-7. PubMed ID: 14699468 [No Abstract] [Full Text] [Related]
11. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? Turkova A; Roilides E; Sharland M Curr Opin Infect Dis; 2011 Apr; 24(2):163-71. PubMed ID: 21301335 [TBL] [Abstract][Full Text] [Related]
12. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Eriksson U; Seifert B; Schaffner A BMJ; 2001 Mar; 322(7286):579-82. PubMed ID: 11238151 [TBL] [Abstract][Full Text] [Related]
13. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. Bes DF; Rosanova MT; Sberna N; Arrizurieta E Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932 [TBL] [Abstract][Full Text] [Related]
14. [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital]. Quinteros A R; Fica C A; Abusada A N; Muñoz C L; Novoa M C; Gallardo A C Rev Chilena Infectol; 2010 Feb; 27(1):25-33. PubMed ID: 20140311 [TBL] [Abstract][Full Text] [Related]
15. Summaries for patients. Itraconazole and amphotericin B to treat fungal infections in patients with cancer who are receiving chemotherapy. Ann Intern Med; 2001 Sep; 135(6):S-39. PubMed ID: 11575279 [No Abstract] [Full Text] [Related]
16. Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity. Falci DR; Lunardi LW; Ramos CG; Bay MB; Aquino VR; Goldani LZ Clin Infect Dis; 2010 Mar; 50(5):e26-9. PubMed ID: 20121575 [TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749 [TBL] [Abstract][Full Text] [Related]
18. Caspofungin versus liposomal amphotericin B for empirical therapy. Schneemann M; Imhof A N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094 [No Abstract] [Full Text] [Related]
19. Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment. Falci DR; dos Santos RP; Wirth F; Goldani LZ Mycoses; 2011 Mar; 54(2):91-8. PubMed ID: 19878457 [TBL] [Abstract][Full Text] [Related]
20. Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever. Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Min WS; Shin WS Korean J Intern Med; 2006 Sep; 21(3):165-72. PubMed ID: 17017665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]